Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovImmune starts PoC study of PBC drug
The results from two previous Phase I trial demonstrated that the drug was safe and well tolerated when administered in healthy volunteers. NI-0801 is a fully human monoclonal
The results from two previous Phase I trial demonstrated that the drug was safe and well tolerated when administered in healthy volunteers. NI-0801 is a fully human monoclonal
CF-301, produced by fermentation at concentrations exceeding 5g/l, is soluble, stable and potent. The Lysins possess a therapeutic window that occurs virtually instantly while the Monoclonal Antibodies remain
As per the previous agreement, both the firms collaborated for the commercialization of Sinclair’s dermatology brands in eleven Asia Pacific countries. Under an agreement, the companies have launched
The US patent no. 8,022,279 includes the key composition features of CPX-351, a liposome formulation that co-encapsulates cytarabine and daunorubicin at a synergistic 5:1 molar ratio. Additionally, the
Under the deal, both the firms have agreed to collaborate on the development of bacteriophage (or phage) based technology for a range of applications. Intralytix CEO John Woloszyn
Xeloda Tablets, 150mg and 500mg, USP are indicated as a treatment of metastatic breast and colorectal cancers. Pursuant to the agreement, the litigation was dismissed on 21 September
The agreement allows FKD to develop and commercialise Merck’s recombinant adenoviral interferon alfa 2b (rAd-IFN) to treat superficial bladder cancer. The agreement also includes an option to develop
Under the contract, the companies will use Vernalis’ fragment and structure-based drug discovery platform against LRRK2. As per the terms of the deal, Vernalis is entitled to receive
The agreement allows the companies to support for the planned clinical trials of a cancer drug – Kevetrin. Cellceutix develops drugs to treat preclinical cancer, anti-inflammatory and autism.
The company has already completed galeterone Phase 1 clinical trial for the treatment of patients with castration resistant prostate cancer (CRPC). The funding has been granted by Novartis